Oral Session 2-9A MM: Global clinical trials

[OS2-9A-1] Pomalidomide, bortezomib, and low dose dexamethasone for relapsed/refractory multiple myeloma

Paul Richardson¹, Albert Oriol², Meral Beksac³, Anna Marina Liberati⁴, Monica Galli⁵, Fredrik Schjesvold⁶, Jindriska Lindsay⁷, Katja Weisel⁸, Darrell White⁹, Thierry Facon¹⁰, Jesus San Miguel¹¹, Kazutaka Sunami¹², Peter O Gorman¹³, Pieter Sonneveld¹⁴, Pawel Robak¹⁵, Sergey Semochkin¹⁶, Steve Schey¹⁷, Xin Yu¹⁸, Thomas Doerr¹⁸, Amine Bensmaine¹⁸, Tsvetan Biyukov¹⁹, Sanae Sakurai²⁰, Mohamed Zaki¹⁸, Kenneth Anderson¹, Meletios Dimopoulos²¹ (1.Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States of America, 2.Institut Catala d Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona, Spain, 3.Ankara University, Cebeci Yerleskesi, Dikimevi, Republic of Turkey, 4.University of Perugia, Terni, Italian Republic, 5.A.O. Papa Giovanni XXIII, U.O. di Ematologia, Bergamo, Italian Republic, 6.Oslo University Hospital, Oslo, Kingdom of Norway, 7.East Kent Hospitals University NHS Foundation Trust, Canterbury, United Kingdom of Great Britain and Northern Ireland, 8.University Hospital of Tuebingen, Tuebingen, Federal Republic of Germany, 9.Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax, Canada, 10.Service des Maladies du Sang, Hopital Claude Huriez, Lille, French Republic, 11.Clinica Universidad de Navarra, CIMA, IDISNA, Pamplona, Spain, 12.National Hospital Organization Okayama Medical Center, Okayama, Japan, 13.Mater Misericordiae University Hospital, University College Dublin, Dublin, Ireland, 14.Erasmus MC Cancer Institute, Rotterdam, Kingdom of the Netherlands, 15.Medical University of Lodz, Lodz, Republic of Poland, 16.Pirogov Russian National Research Medical University, Moscow, Russian Federation, 17.Department of Hematology, King's College London, London, United Kingdom of Great Britain and Northern Ireland, 18.Celgene Corporation, Summit, United States of America, 19.Celgene International Sarl, Boudry, Swiss Confederation, 20.Celgene K.K., Tokyo, Japan, 21National and Kapodistrian University of Athens, Athens, Republic of Cyprus)